Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2011

01-09-2011

The Role of Risk Communication in the Care of Osteoporosis

Author: E. Michael Lewiecki

Published in: Current Osteoporosis Reports | Issue 3/2011

Login to get access

Abstract

Risk assessment and communication of risk are essential components in the care of patients with osteoporosis. The risk of fracture in an untreated patient can be estimated with measurement of bone mineral density, consideration of clinical risk factors, and the use of a validated fracture risk assessment algorithm. When fracture risk is high, pharmacologic therapy to reduce the risk of fracture is indicated, provided no contraindications are present. Initiation, compliance, and persistence with therapy may be enhanced when the patient fully understands the risk of fracture if no treatment is given, as well as the expected benefit and potential risks of treatment. Optimal clinical outcomes with treatment may in part depend on the clinician’s skill in communicating risk with the patient, understanding the patient’s concerns, and reaching a collaborative treatment decision that is medically reasonable and acceptable to the patient.
Literature
1.
World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO; 1994.
2.
Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999–2005. J Bone Miner Res. 2008;23(7):1061–7.PubMedCrossRef
3.
Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45(9):902–6.PubMedCrossRef
4.
McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–87.PubMedCrossRef
5.
Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(12):965–8.PubMedCrossRef
6.
Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003–8.PubMedCrossRef
7.
Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431–44.PubMedCrossRef
8.
Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229.PubMedCrossRef
9.
Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. UK: University of Sheffield. Printed by the University of Sheffield; 2007.
10.
Leslie WD, Tsang JF, Lix LM. Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res. 2009;24(2):353–60.PubMedCrossRef
11.
Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone. 2009;44:1049–54.PubMedCrossRef
12.
McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy–additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009;20(5):811–7.PubMedCrossRef
13.
Lewiecki EM. Fracture risk assessment in clinical practice: T-scores, FRAX, and beyond. Clinic Rev Bone Miner Metab. 2009;8(3):101–12.CrossRef
14.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.PubMedCrossRef
15.
16.
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–89.PubMedCrossRef
17.
Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRef
18.
19.
20.
21.
Rossini M, Bianchi G, Di MO, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914–21.PubMedCrossRef
22.
23.
Lewiecki EM, Binkley N. Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr Pract. 2009;24(10):1643–6.
24.
Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120–4.PubMedCrossRef
25.
• Giangregorio L, Dolovich L, Cranney A, et al. Osteoporosis risk perceptions among patients who have sustained a fragility fracture. Patient Educ Couns. 2009;74(2):213–20. This study shows that patients commonly underestimate the risk of future fracture following a fracture and thereby be less likely to be motivated to be treated to reduce fracture risk.PubMedCrossRef
26.
Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 Suppl 1):S12–7.PubMedCrossRef
27.
Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients’ decisions be judged? A review of the literature. Med Decis Mak. 1999;19(4):428–34.CrossRef
28.
Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. J Natl Cancer Inst Monogr. 1999;25:44–51.PubMed
29.
Waitzkin H. Doctor-patient communication. Clinical implications of social scientific research. JAMA. 1984;252(17):2441–6.PubMedCrossRef
30.
Braddock III CH, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282(24):2313–20.PubMedCrossRef
31.
Whitney SN. A new model of medical decisions: exploring the limits of shared decision making. Med Decis Mak. 2003;23(4):275–80.CrossRef
32.
Lloyd AJ, Hayes PD, London NJ, et al. Patients’ ability to recall risk associated with treatment options. Lancet. 1999;353(9153):645 [Research Letter].PubMedCrossRef
33.
Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997;127(11):966–72.PubMed
34.
Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Mak. 2001;21(1):37–44.CrossRef
35.
Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89–90.PubMedCrossRef
36.
•• Galesic M, Garcia-Retamero R, Gigerenzer G. Using icon arrays to communicate medical risks: overcoming low numeracy. Health Psychol. 2009;28(2):210–6. This is a thought-provoking study of the challenges in communicating risk to patients and methods to enhance better understanding of risk.PubMedCrossRef
37.
Gaissmaier W, Gigerenzer G. Statistical illiteracy undermines informed shared decision making. Z Evid Fortbild Qual Gesundhwes. 2008;102(7):411–3.PubMedCrossRef
38.
• Sambrook PN, Chen JS, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust. 2010;193(3):154–6. This is a case study of the harm to patients that may be the result of inaccurate and misleading news reporting of possible adverse effects of pharmacologic therapy for osteoporosis.PubMed
39.
O’Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009;(3):CD001431.
40.
Meyer G, Steckelberg A, Muhlhauser I. Analysis of consumer information brochures on osteoporosis prevention and treatment. Ger Med Sci. 2007;5:1–9.
41.
Lewiecki EM, Rudolph LA, Kiebzak GM, et al. Assessment of osteoporosis-website quality. Osteoporos Int. 2006;17(5):741–52.PubMedCrossRef
42.
Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13(6):608–18.PubMedCrossRef
43.
Schapira MM, Nattinger AB, McHorney CA. Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Mak. 2001;21(6):459–67.
44.
Lewiecki EM. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13(4):335–45.PubMedCrossRef
45.
Boudreau JD, Cassell E, Fuks A. Preparing medical students to become attentive listeners. Med Teach. 2009;31(1):22–9.PubMedCrossRef
46.
Winzenberg T, Oldenburg B, Frendin S, et al. The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260]. BMC Public Health. 2006;6:1–12.CrossRef
47.
Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89:321–5.PubMedCrossRef
48.
Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117–23.PubMedCrossRef
49.
Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009;20(4):625–30.PubMedCrossRef
50.
Pencille LJ, Campbell ME, Van Houten HK, et al. Protocol for the osteoporosis choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials. 2009;10:1–9.CrossRef
Metadata
Title
The Role of Risk Communication in the Care of Osteoporosis
Author
E. Michael Lewiecki
Publication date
01-09-2011
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 3/2011
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-011-0056-1

Other articles of this Issue 3/2011

Current Osteoporosis Reports 3/2011 Go to the issue

ReviewPaper

Osteoporosis: A Paradox in Ankylosing Spondylitis

ReviewPaper

Choosing a Treatment for Patients at the Time a Fracture is Presented

ReviewPaper

Diagnostic Thresholds in Osteoporosis: How Are They Used in Clinical Trials?

ReviewPaper

Minor, Major, Low-Trauma, and High-Trauma Fractures: What Are the Subsequent Fracture Risks and How Do They Vary?

ReviewPaper

Effects of Anti-osteoporosis Medications on Fracture Healing

ReviewPaper

A Review of Osteoporosis Diagnosis and Treatment Options in New and Recently Updated Guidelines on Case Finding Around the World